PT-141 (bremelanotide) is an FDA-approved injectable that acts on the brain to boost sexual desire in premenopausal women. Here's how it works and its risks.
PT-141 (bremelanotide, sold as Vyleesi) is a prescription medication that raises sexual desire in premenopausal women diagnosed with hypoactive sexual desire disorder (HSDD). It works in the brain by activating melanocortin receptors rather than by improving blood flow or changing hormone levels. That distinction is why PT-141 is best described as a desire drug, not an arousal or lubrication product.
How PT-141 Works in the Female Body
PT-141 is a synthetic version of alpha-melanocyte-stimulating hormone, a peptide the body already produces. Once injected, it binds to melanocortin receptors — mainly MC4R — in the hypothalamus and other parts of the central nervous system.
Those receptors sit on pathways that regulate dopamine, the neurotransmitter linked to motivation and reward. Activating them appears to increase interest in sex and narrow the gap between wanting sex and responding to it.
- It is central, not local. PT-141 does not act directly on genital tissue the way a PDE5 inhibitor does.
- It is not a hormone. It does not raise estrogen, progesterone, or testosterone.
- It still needs context. In trials, women reported benefit when sexual stimulation was present; it is not a switch that creates desire out of nothing.
In the Phase 3 trials that supported FDA approval, premenopausal women with HSDD reported modest but measurable increases in desire and reductions in related distress compared with placebo. The effect size was real but not dramatic.
PT-141 Compared With Other Options for Low Desire
PT-141 is one of only two drugs approved in the United States for low sexual desire in women, and it works very differently from the other options people ask about.
| Treatment | FDA-approved for | How it works | Typical use | Common side effects |
|---|---|---|---|---|
| Bremelanotide (PT-141 / Vyleesi) | Premenopausal women with acquired, generalized HSDD | Melanocortin receptor agonist in the brain | 1.75 mg injection under the skin about 45 minutes before sex; max 8 doses per month | Nausea, flushing, headache, injection site reactions |
| Flibanserin (Addyi) | Premenopausal women with acquired, generalized HSDD | Adjusts serotonin signaling in the brain | 100 mg by mouth at bedtime, daily | Dizziness, sleepiness, low blood pressure, nausea |
| Sildenafil (Viagra) | Men with erectile dysfunction | PDE5 inhibitor that increases genital blood flow | Oral tablet as needed | Headache, flushing, nasal congestion |
| Testosterone (off-label in women) | Not approved for women in the US | Androgen receptor activity | Varies; compounded creams, gels, or pellets | Acne, unwanted hair growth, voice changes |
PT-141 has also been studied as a treatment for erectile dysfunction, so many people researching it start with what does pt-141 do for men and end up here. It is not FDA-approved for men in any form.
Who PT-141 Is Approved For — and Who It Isn't
The Vyleesi label covers premenopausal women with acquired, generalized HSDD, meaning the low desire developed over time rather than being lifelong and is not limited to one situation or partner.
PT-141 is not FDA-approved for postmenopausal women, and the pivotal trials that led to approval enrolled premenopausal participants. Some clinicians prescribe the peptide off-label for postmenopausal women, but the supporting evidence in that group is limited.
PT-141 is also not approved for women whose low desire is caused primarily by relationship problems, medication side effects, untreated depression, or pelvic pain. Those issues usually need to be addressed directly first.
Dosing, Timing, and the Nasal Spray Question
The approved dose is 1.75 mg injected under the skin of the abdomen or thigh, typically about 45 minutes before anticipated sexual activity. The label caps use at one dose every 24 hours and no more than eight doses per month.
A common question from patients is how fast does pt-141 work for women — most report onset within 30 to 60 minutes after injection, with effects tapering off over a few hours. It is not a daily medication, and taking it more often does not improve results.
There is no FDA-approved nasal spray. A pt 141 nasal spray for women has been studied in clinical research for female sexual dysfunction, and some online sellers market unapproved nasal products, but dosing accuracy and purity are not guaranteed outside the regulated supply chain. A pt-141 dosage calculator for women offered by a vendor is not a substitute for a prescriber's instructions.
Side Effects and Safety Profile
The most frequently reported pt-141 for women side effects are nausea, flushing, and headache. Nausea is the single most common reason women stop using it, and it tends to improve with later doses for some users but not all.
- Injection site reactions such as pain, redness, or itching
- Vomiting, cough, dizziness, or hot flashes
- Transient increases in blood pressure after dosing
- Focal hyperpigmentation (dark patches on skin, gums, or nails) with repeated or frequent use
Bremelanotide is contraindicated in women with uncontrolled high blood pressure or known cardiovascular disease, because it can raise blood pressure for several hours after injection. It is not recommended during pregnancy or breastfeeding, and its safety in those situations has not been established.
Anyone with heart disease, low blood pressure, or a history of fainting should talk with a healthcare professional before using PT-141. Combining it with alcohol or blood pressure medications has not been well studied.
Prescriptions, Gray-Market Peptides, and Legal Status
In the United States, the answer to do you need a prescription for pt-141 is yes — Vyleesi is a prescription-only product, and it is dispensed through specialty pharmacies rather than regular retail chains.
Unapproved "research grade" vials are widely sold online. They are not manufactured to the same standards, may be under- or over-dosed, and may contain contaminants. Many of these vials ship as a powder that has to be dissolved before use, which is why buyers ask what does bac water do for peptides; bacteriostatic water is sterile water with a preservative that keeps a reconstituted peptide stable for longer, but it does not change what the peptide does.
Because of the hyperpigmentation risk, the manufacturer limits monthly dosing, and buying from unregulated sources removes that safeguard entirely.
The Bottom Line
PT-141 is a brain-acting melanocortin agonist that the FDA approved as Vyleesi for premenopausal women with acquired, generalized HSDD. PT-141 is not approved for postmenopausal women or for men, and it is not a hormone or a blood-flow drug. Its benefits are modest, its most common side effect is nausea, and its use should be supervised by a clinician who can review blood pressure history and other risk factors.
Frequently Asked Questions
Does PT-141 make women physically aroused, or does it increase desire?
PT-141 is approved for low sexual desire, not for lubrication or immediate physical arousal. It acts on brain pathways involved in motivation and reward, so most users describe it as a stronger interest in sex rather than an automatic physical response. Genital response still depends on stimulation, hormones, and other factors.
Is PT-141 effective for postmenopausal women?
There is no FDA approval for PT-141 in postmenopausal women, and the trials that led to approval enrolled only premenopausal participants. Some clinicians prescribe it off-label, but the evidence in postmenopausal women is limited. Anyone in that group should review risks and alternatives with a healthcare professional.
How long does one dose of PT-141 last?
Effects usually begin within 30 to 60 minutes after injection and can last for several hours. The label limits use to one dose in any 24-hour period and no more than eight doses per month. Taking more does not improve results and increases the risk of nausea and focal hyperpigmentation.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.